Varietal description of two genotypes of manzano chili pepper (Capsicum pubescens Ruiz & Pav.)

Objective: the objective of this research work was to obtain the varietal description of two varieties of chile manzano in Las Montañas in the center of Veracruz, México. Design/methodology/approach: the varietal characterization module was established under greenhouse conditions at the Centro de Bachillerato Tecnológico Agropecuario No. 99 in the municipality of Coscomatepec de Bravo. The recorded descriptors were in accordance with the International of Plant Genetic Resources Institute for Capsicum and the Graphic Handbook for Variety Description of manzano hot pepper. The plants were characterized from the seedling to the adult plant. The agronomic management of the crop was carried out in accordance with the manual for the production of manzano hot pepper in Las Montañas of the state of Veracruz. Results: all qualitative descriptors were constant for the two varieties MEXUVNE1-15-C2 and MEXUVCU1-16-C2 from seedling to fruiting; in contrast, there were dissimilarities in plant height, stem, leaf, flower, fruit and seed dimensions. Limitations of the study/implications: the pandemic caused by COVID-19 was the main limitation so that some descriptors were not recorded in a timely manner as indicated in the Graphic Handbook. Findings/conclusions: both varieties are very similar; however, the greatest distinction was in the quantitative type descriptors such as: plant height, fruit length, fruit diameter and number of seeds.Objective: The objective of this research study was to obtain the varietal description of two varieties of manzano chili pepper in Las Montañas region, in central Veracruz, Mexico. Design/methodology/approach: The varietal characterization module was established under greenhouse conditions. The markers recorded were in accordance with the International Plant Genetic Resources Institute for Capsicum and the Graphic Handbook for Variety Description of manzano chili pepper. The plants were characterized from seedling in greenhouse to adult plant. The agronomic management of the crop was carried out in accordance with the manual for the production of manzano chili pepper in Las Montañas, state of Veracruz. Results: All qualitative markers were constant for the two varieties, MEXUVNE1-15-C2 and MEXUVCU1-16-C2, from seedling to fruit setting. In contrast, there were dissimilarities in plant height, and stem, leaf, flower, fruit and seed dimensions. Study limitations/implications: The pandemic caused by COVID-19 was the main limitation, resulting in some markers not being recorded in a timely manner as indicated in the Graphic Handbook. Findings/conclusions: Both varieties are very similar; however, the greatest distinction was in the quantitative markers, such as: plant height, fruit length, fruit diameter and number of seeds

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)